Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Местнораспространенный и метастатический гормонопозитивный рак молочной железы: проблемы терапии и перспективы применения лапатиниба в комбинации с ингибиторами ароматазы в качестве терапии первой линии
Местнораспространенный и метастатический гормонопозитивный рак молочной железы: проблемы терапии и перспективы применения лапатиниба в комбинации с ингибиторами ароматазы в качестве терапии первой линии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. EBCTG Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451–67.
2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513–29.
3. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003; 8: 335–41.
4. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9: 447S–54.
5. Wolff AC, Hammond WE, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–45.
6. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7: 4338s–42s (discussion 4411s–2).
7. Chung YL, Sheu ML, Yang SC et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Internat J Cancer 2002; 97: 306–12.
8. Sabnis The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005; 65 (9): 3903–10.
9. Vogel et al Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (3): 719–26.
10. Slamon et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783–92.
11. Stemmler J, Kahlert S, Siekiera W et al. Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): incidence and survival. J Clin Oncol 2005; 23 (16 suppl.).
12. Perez EA, Byrne JA, Hammond IW et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol 2006; 24 (18 suppl.).
13. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652–9.
14. Chu I, Blackwell K, Chen S et al. The Dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005; 65: 18–25.
15. Cameron D et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; Jan 11.
16. NCCN Practice Guidelines in Oncology - breast cancer v.1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed: June 2009
17. AGO Group's breast cancer guidelines (Germany). Available at: http://www.ago-online.org. Accessed: July 2008.
18. Johnston S. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27 (33).
2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513–29.
3. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003; 8: 335–41.
4. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9: 447S–54.
5. Wolff AC, Hammond WE, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–45.
6. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7: 4338s–42s (discussion 4411s–2).
7. Chung YL, Sheu ML, Yang SC et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Internat J Cancer 2002; 97: 306–12.
8. Sabnis The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005; 65 (9): 3903–10.
9. Vogel et al Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (3): 719–26.
10. Slamon et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783–92.
11. Stemmler J, Kahlert S, Siekiera W et al. Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): incidence and survival. J Clin Oncol 2005; 23 (16 suppl.).
12. Perez EA, Byrne JA, Hammond IW et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol 2006; 24 (18 suppl.).
13. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652–9.
14. Chu I, Blackwell K, Chen S et al. The Dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005; 65: 18–25.
15. Cameron D et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; Jan 11.
16. NCCN Practice Guidelines in Oncology - breast cancer v.1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed: June 2009
17. AGO Group's breast cancer guidelines (Germany). Available at: http://www.ago-online.org. Accessed: July 2008.
18. Johnston S. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27 (33).
Авторы
И.В.Поддубная
Кафедра онкологии ГОУ ДПО РМАПО, Москва
Кафедра онкологии ГОУ ДПО РМАПО, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.